Dr. Cerilli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1300 N 12th St
Suite 300
Phoenix, AZ 85006Phone+1 602-687-7468Fax+1 602-264-9101
Education & Training
University of MichiganFellowship, Gastroenterology, 2011 - 2012
University of Texas Southwestern Medical CenterChief Residency, Pathology-Anatomic and Clinical, 1998 - 1999
University of Virginia Medical CenterFellowship, Cytopathology, 1998 - 1999- University of Texas Southwestern Medical CenterResidency, Pathology-Anatomic and Clinical, 1994 - 1998
- University of Texas Southwestern Medical CenterInternship, Internal Medicine, 1993 - 1994
Emory University School of MedicineClass of 1993
Duke UniversityBS, 1985 - 1989
Certifications & Licensure
AZ State Medical License 2012 - 2026
UT State Medical License 2022 - 2026
CO State Medical License 2022 - 2025
NM State Medical License 2004 - 2018
MI State Medical License 2011 - 2015
VA State Medical License 1999 - 2006
TX State Medical License 1994 - 2001- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Cytopathology
Awards, Honors, & Recognition
- Phoenix Top Doc 2017, 2018
- Residency Teaching Award 2012
- Magna Cum Laude, Duke University
- Join now to see all
Publications & Presentations
PubMed
- 21 citationsA Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.Julie E. Bauman, Keith D. Eaton, Sarah G. Wallace, Laurie L. Carr, Sang Joon Lee
BMC Cancer. 2012-10-03 - 31 citationsThe Differential Diagnosis of Colitis in Endoscopic Biopsy Specimens: A Review ArticleLisa A. Cerilli, Joel K. Greenson
Archives of Pathology & Laboratory Medicine. 2012-07-31 - 54 citationsPhase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimenClaire F. Verschraegen, Hugo Arias-Pulido, Sang Joon Lee, Sujana Movva, Lisa A. Cerilli
Annals of Oncology. 2012-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
